If you're having trouble viewing this email, see it on the Web.
Technet21

Home | Invite Others | Digest Archives  
Posts:

technet21 postspacerPNIDs—For How Long Should They Continue?

technet21 postspacer10 Vaccines Can Be Given Intradermally To Spare Costs As Well As Doses

technet21 postspacerWhat's in a Name?
Issue 27, 2 November 2009
 
Editorial Note

Darin Zehrung adds to the discussion on intradermal vaccines. Riad Alshibli answers the question whether there is need to proceed with Nation Immunization Days (NIDs) when an immunization coverage rate of more than 95% has been achieved, initiating an interesting discussion on the subject. And, finally, a term has been identified for storing and transporting vaccines outside of the 2-8°C range.


by Riad Alshibli

I have faced one question regarding NIDs, which is: if one of the governorates or provinces in any country achieves a routine immunization coverage rate of more than 95%, is there need to proceed with NIDs? This question was raised in Iraq.

... it depended on national strategies and on how long the coverage rate has been more than 95% ...

[Read more]

Comment on this post by email or on the web

by Omesh Bharti

Although encouraging results have been obtained with ID delivery of 1/5 of the standard dose for several vaccines, most notably rabies and influenza, the number of clinical trials that have been performed is small and it is not yet certain that such a significant reduction in dose will be possible with all vaccines. For example, the recently licensed ID influenza vaccine (from Sanofi-Pasteur) is a 40% reduction in dose from the standard IM formulation. Less dramatic reductions in dose size might be more realistic. [Darin Zehrung]

[Read more]

Comment on this post by email or on the web

by Michel Zaffran

Many thanks to the many readers who have provided feedback and input.

My colleague Steve McCarney of PATH has consolidated all the inputs received into a background document that was presented at the last WHO Technology and Logistics Advisory Committee (TLAC) meeting in September. We are proposing that the terminology "Controlled Temperature Chain," (CTC) be now used to describe storing and transporting vaccines beyond the 2-8°C temperature range, as appropriate to each vaccine's stability profile.

[Read more]

Comment on this post by email or on the web

 

  Web Highlights:
  technet21 post

A new vaccine adverse event reporting system website has been launched
  technet21 post

Marc Koska: 1.3m reasons to re-invent the syringe
  technet21 post

Developing countries swamped in healthcare rubbish

 

Register

If you have contributions to make or thoughts to share with others on TechNet21, you can write to the moderator or post directly on the web forums. Click here to change your subscription settings or unsubscribe from the mailing list.

TechNet21 is generously supported by the Bill and Melinda Gates Foundation, under the oversight of WHO and UNICEF. The information in this forum is provided by users, as a service. All contributions are reviewed prior to posting, and all postings are attributed to the authors. The details given in emails will not be voluntarily shared or sold to any outside company and will only be used for verification and to identify postings, if necessary. The authors are solely responsible for their submissions, and the readers are solely responsible for the interpretation of these submissions. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to this forum.

For posts where the author is a WHO staff member, the author alone is reponsible for the views expressed and they do not necessarily represent the decisions, guidelines, recommendations or policies of WHO.